Peptides for healing & recovery

Peptides for healing are short amino-acid chains studied for their effects on the biology of tissue repair: forming new blood vessels, moving repair cells into an injury, regulating inflammation, and rebuilding the extracellular matrix. They are discussed for tendon and ligament injuries, muscle strains, joint pain, slow-healing wounds, and inflammation of the gut and skin.

The category is popular and the mechanisms are genuinely interesting. The human evidence, for most of these compounds, is thin — and in July 2026 the regulatory ground shifted under several of the best known. This guide covers both honestly, so that patients and prescribers can separate what is established from what is promising and what is only marketed.

Each compound has its own library page, and questions about dosing, side effects, and combinations are answered on dedicated pages linked below. For the fundamentals, start with what are peptides.

Tendon, ligament, and joint injuries are the most common reason patients ask about repair peptides, because these tissues have a poor blood supply and heal slowly. BPC-157 has the largest preclinical literature here, including accelerated tendon healing in surgical transection models and improved ligament recovery. TB-500 is discussed for its role in moving repair cells into the injury.

In humans, the evidence for either compound in tendon repair or joint pain is limited to small reports and clinical experience. FDA's July 2026 briefing reviewed tendonitis among BPC-157's nominated uses and found the effectiveness evidence insufficient. Conventional care — load management, progressive rehabilitation, and, where indicated, approved injections or surgery — remains the evidence-based foundation, and peptides are at most a supplement to it.

For the evidence detail, see our BPC-157 clinical research review and TB-500 and cell migration. The two are often combined as the wolverine stack.

KPV, a three-amino-acid fragment of alpha-melanocyte-stimulating hormone, is the peptide most associated with inflammation — particularly in the gut and skin. Its research is concentrated in inflammatory bowel disease models, which is a narrower and more specific base than the general "gut healing" framing suggests. Our KPV for IBS and leaky gut post explains why the distinction between IBD and IBS matters, and KPV in GI and skin inflammation covers the research.

BPC-157's origins are also gastrointestinal: it derives from a protective protein in gastric juice, and much of its early research involved gut injury models. Its FDA nomination sought use in ulcerative colitis, Crohn's disease, and celiac disease — and FDA found a single small ulcerative colitis trial with limited detail, which it judged insufficient.

Inflammation that drives chronic pain or disease has many causes. Peptides do not replace diagnosis, and several well-studied, FDA-approved treatments exist for inflammatory bowel disease.

GHK-Cu, a copper-binding tripeptide, has the most consistent evidence in this category for skin — collagen synthesis, wound healing, and skin remodeling, particularly in topical use. It is covered in depth on our peptides for skin hub and the GHK-Cu library page.

Thymosin alpha-1 sits apart from the tissue-repair peptides. It is an immune modulator rather than a structural repair signal, and it has a regulatory history the others lack: it is approved in a number of countries outside the US as thymalfasin. It is discussed for recovery from illness and immune resilience. LL-37, the body's own antimicrobial peptide, is studied for chronic wounds and infection, but carries more safety questions than most compounds in this group — see the LL-37 page.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with a licensed 503A compounding partner. Practices evaluating a repair-and-recovery formulary can review our repair and recovery product connections, and prescribers can start at For Providers.